Amy C. Nieto delves into the latest advancements in non-small cell lung cancer (NSCLC) treatment, including sunvozertinib, a newly-approved therapy for challenging EGFR exon 20 insertion mutations.

administrator
Amy C. Nieto delves into the latest advancements in non-small cell lung cancer (NSCLC) treatment, including sunvozertinib, a newly-approved therapy for challenging EGFR exon 20 insertion mutations.